2BEHRJJ (200414) -- BEIJING, April 14, 2020 (Xinhua) -- A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical

Covid-19

1.2 million doses of Vero Cell arrive from China

By Khabarhub

October 27, 2021

KATHMANDU: As many as 1.2 million doses of Vero Cell purchased under the COVAX facility have arrived in Kathmandu.

COVID-19 vaccines have been brought from China at the Tribhuvan International Airport at 9 am.

Sagar Dahal, the chief of the Department of Health Services, informed that out of 5.9 million doses of Vero Cell procured by the Nepal government from China to procure, the first lot has arrived this morning.

The newly brought vaccines will be stored at the vaccine storge center in Teku, informed Upendra Dhungana, the Department of Supplies Management.